fda warning letters compounding semaglutide october 2025 issued 25 to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of September 8, 2025: FDA launches

Article published: 6/11/26 GLP-1 and the New Consumer Economy Somewhere between the hot sauce and the expired salad dressing sits a weekly injection responsible for rewriting the consumer economy

Dual fortification of salt with iodine and micronized ferric pyrophosphate: A randomized, double-blind, controlled trial

However, while these benefits are enticing, they must be weighed against potential risks, especially for those with existing kidney concerns

Tirzepatide 5 mg converts to retatrutide starting at 2 mg with target of 4 mg

Its rise in popularity is largely due to its ability to address the biological factors behind weight gain rather than relying solely on willpower

J Physiol Pharmacol , 60(Suppl 7), 191-96